Entasis’ Nuzolvence and GSK’s Blujepa have received approval as the first new antibiotics for the treatment of gonorrhoea in over 30 years in the United States. This milestone reflects a significant advancement in the ongoing battle against antibiotic-resistant strains of Neisseria gonorrhoeae, which have increasingly challenged existing treatment protocols.
The emergence of these new therapies is critical, given the World Health Organization’s classification of gonorrhoea as a high-priority pathogen due to its evolving resistance. The approval of Nuzolvence and Blujepa not only provides healthcare professionals with additional tools to combat this public health issue but also signals a renewed focus on antibiotic development in an era where resistance is a growing concern.
As these drugs enter the market, stakeholders across the pharmaceutical landscape—including regulatory bodies, quality assurance teams, and supply chain professionals—must prepare for the implications on treatment guidelines, patient management, and potential shifts in antibiotic stewardship practices.
Use the database as your supply chain compass →
